Evidence map›Paper›PMID 34434192›Full record

SynthesisFrontiers in immunology2021

Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis.

Andrea Botticelli, Alessio Cirillo, Lidia Strigari, Filippo Valentini, Bruna Cerbelli, Simone Scagnoli, Edoardo Cerbelli, Ilaria Grazia Zizzari, Carlo Della Rocca, Giulia D'Amati and 5 more

Open access · goldAbstract readComparative StudySystematic ReviewNetwork Meta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 2 pooled it
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 2 syntheses or guidelines pooled it, 97 citations in OpenAlex.

  1. Pooled it
  2. Comparative safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and network meta-analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024
    Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Introduction to Oral Immunity.Advances in experimental medicine and biology · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Andrea BotticelliDepartment of Clinical and Molecular Oncology, "Sapienza" University of Rome, Rome, Italy.
Alessio CirilloDepartment of Radiological, Oncological, and Anatomo-Pathological Science "Sapienza", University of Rome, Rome, Italy.
Lidia StrigariMedical Physics Unit, "S. Orsola-Malpighi" Hospital, Bologna, Italy.
Filippo ValentiniDepartment of Radiological, Oncological, and Anatomo-Pathological Science "Sapienza", University of Rome, Rome, Italy.
Bruna CerbelliDepartment of Radiological, Oncological, and Anatomo-Pathological Science "Sapienza", University of Rome, Rome, Italy.
Simone ScagnoliDepartment of Radiological, Oncological, and Anatomo-Pathological Science "Sapienza", University of Rome, Rome, Italy.
Edoardo CerbelliDepartment of Radiological, Oncological, and Anatomo-Pathological Science "Sapienza", University of Rome, Rome, Italy.
Ilaria Grazia ZizzariDepartment of Experimental Medicine, University Sapienza, Rome, Italy.
Carlo Della RoccaDepartment of Medico-Surgical Sciences and Biotechnology, Polo Pontino, Sapienza University, Roma, Italy.
Giulia D'AmatiDepartment of Radiological, Oncological, and Anatomo-Pathological Science "Sapienza", University of Rome, Rome, Italy.
Antonella PolimeniOdontostomatological and Maxillo-Facial Science, 'Sapienza' University of Rome, Rome, Italy.
Marianna NutiDepartment of Experimental Medicine, University Sapienza, Rome, Italy.
Marco Carlo MerlanoMedical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo (Turin), Italy.
Silvia MeziDepartment of Radiological, Oncological, and Anatomo-Pathological Science "Sapienza", University of Rome, Rome, Italy.
Paolo MarchettiDepartment of Clinical and Molecular Oncology, "Sapienza" University of Rome, Rome, Italy.
Sapienza University of Rome · ITCandiolo Cancer Institute · ITPoliclinico S.Orsola-Malpighi · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The monoclonal antibodies anti-programmed death protein-1 (anti-PD-1) nivolumab and pembrolizumab are the first immune checkpoint inhibitors (ICIs) approved for treatment of recurrent/metastatic head and neck carcinoma R/M HNSCC in first line and in platinum refractory disease. This network meta-analysis aims to investigate the efficacy of anti-PD-1- Methods: We did a systematic literature review and network meta-analysis (NMA) of randomized controlled trials (RCTs) in PubMed, ClinicalTrials.gov, Embase, Medline, the Cochrane Central Register of Controlled Trials, Web of Science. Our search identified a total of five randomized controlled trials: Keynote 040, Keynote 048, Eagle, Condor, Checkmate 141. These trials included 3001 patients. Treatment was sub-categorized into PD-L1-based, PD-1-based, and standard chemotherapy. Treatments were indirectly compared with anti-PD-L1-based therapy. Results: The network meta-analysis demonstrated no significant differences in OS between different subgroups except for the metastatic patients in which anti-PD-1-based therapy was associated with significantly less risk of death. Furthermore, anti-PD-1-based therapy appeared to be effective in smoker patients and in human papilloma-negative (HPV) patients. Conversely, anti-PD-L1-based therapy seems to be better efficient in female patients, in locally recurrent setting and in HPV positive patients. Conclusion: This is the first NMA study that aimed to indirectly compare anti-PD-1- and anti-PD-L1-based therapy in HNSCC patients. The results of our NMA could help define a profile of patient responder or resistant to specific classes of immune drugs and can be used to guide/design future studies in the novel scenario of precision immune-oncology.

Indexed as

AgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenCarcinomaCisplatinClinical Trials as TopicCombined Modality TherapyEvidence-Based MedicineFemaleFluorouracilHead and Neck NeoplasmsHumansImmune Checkpoint InhibitorsImmunotherapyAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedB7-H1 AntigenCD274 protein, humanCisplatindurvalumabFluorouracilImmune Checkpoint InhibitorsNivolumabPDCD1 protein, humanpembrolizumabProgrammed Cell Death 1 Receptortremelimumabanti–PD-1anti–PD-L1immunotherapymetastatic head and neck cancernetwork meta-analysis

Identifiers

PMID34434192
PMCPMC8380817
OpenAlexW3189212793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.